EQT Completes Final Galderma Sell-Down
Analysis based on 9 articles · First reported Mar 13, 2026 · Last updated Mar 16, 2026
The successful final sell-down of Galderma by EQT AB, realizing CHF 21 billion, signals strong investor confidence in the dermatology sector and private equity's ability to create significant value. Galderma's nearly tripled share price since its 2024 IPO further reinforces positive market sentiment for high-growth, science-backed companies.
EQT AB has completed its final sell-down of shares in Galderma, a global dermatology company, through the largest sponsor-backed block trade in history. This transaction generated aggregate gross proceeds of approximately CHF 4.9 billion, with EQT VIII receiving CHF 1.3 billion. In total, EQT AB has realized CHF 21 billion from the sale of Galderma shares, marking its largest value-creation outcome. EQT AB, along with co-investors, carved out Galderma from Nestlé in October 2019. Under EQT AB's ownership, Galderma significantly accelerated revenue growth, increased R&D investment, and built a broad portfolio of clinically-proven brands. Galderma completed one of Europe's largest IPOs in 2024, and its share price has nearly tripled since then. Investment banks including Goldman Sachs, Morgan Stanley, UBS, Citigroup, Jefferies Financial Group===Jefferies Group, and JPMorgan Chase===J.P. Morgan & Co. acted as joint global coordinators and bookrunners for the placement.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard